Clinical Trial Update: Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for inhaled nitric oxide (INOpulse DS) in pulmonary arterial hypertension (PAH) has completed enrollment/status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Pulmonary Hypertension

Drugs mentioned

• INOpulse DS (inhaled nitric oxide) (nitric oxide)

Snippet

Sponsor: Bellerophon Pulse Technologies | Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension | Phase 2 | Status: COMPLETED